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Abstract Sphingolipids including ceramides and its
derivatives such as ceramide-1-phosphate, glucosylcera-
mide (GlcCer), and sphingosine-1-phosphate are essential
structural components of cell membranes. They now rec-
ognized as novel bioeffector molecules which control var-
ious aspects of cell growth, proliferation, apoptosis, and
drug resistance. Ceramide, the central molecule of sphin-
golipid metabolism, generally mediates anti-proliferative
responses such as inhibition of cell growth, induction of
apoptosis, and/or modulation of senescence. There are two
major classes of sphingolipids. One of them is glyco-
sphingolipids which are synthesized from the hydrophobic
molecule, ceramide. GlcCer, generated by glucosylcera-
mide synthase (GCS) that transfers the glucose from UDP-
glucose to ceramide, is an important glycosphingolipid
metabolic intermediate. GCS regulates the balance between
apoptotic ceramide and antiapoptotic GlcCer. Downregu-
lation or inhibition of GCS results in increased apoptosis
and decreased drug resistance. The mechanism underlying
the drug resistance which develops with increased gluco-
sylceramide expression is associated with P-glycoprotein.
In various types of cancers, overexpression of GCS has been
observed which renders GCS a good target for the treatment
of cancer. This review summarizes our current knowledge
on the structure and functions of glucosylceramide synthase
and glucosylceramide and on the roles of glucosylceramide
synthase in cancer therapy and drug resistance.
Keywords Glucosylceramide synthase  Cancer therapy 
Glucosylceramide  Drug resistance  Ceramide 
Sphingolipid
Introduction
Sphingolipids (SLs) are a family of lipids that play
essential roles as structural cell membrane components that
contribute to the regulation of the fluidity and the sub-
domain structure of the lipid bilayers [1–4]. These mem-
brane lipids do not only function as structural components
of the cell membrane, but they also possess important roles
in signal transduction as second messengers and in vital
cellular processes such as differentiation, migration,
apoptosis, cell proliferation, cell cycle arrest, senescence,
and inflammation [5–8]. The basic structure of all sphin-
golipids consists of up to three components: a sphingoid
backbone (such as sphingosine, 1,3-dihydroxy-2-amino-
alkane and its derivatives), an amide-linked long-chain
fatty acid tail, and several distinct modifications of the head
group [9, 10]. The head groups define the various sphin-
golipid classes, with a hydroxyl group found in ceramides;
phosphorylcholine, in sphingomyelin (SM); and carbohy-
drates, in the various glycosphingolipids [11, 12]. The
sphingoid backbone is an aliphatic 2-amino-1,3-diol. From
this basic lipid, addition of fatty acids that are typically
16–26 carbon atoms in length, phosphate/sulfate groups,
and carbohydrates results in a large group of lipids with
numerous physiological roles [10, 11, 13, 14].
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Briefly, sphingolipids are synthesized de novo from
serine and palmitate, which condense serine and palmitoyl
CoA to form 3-keto-dihydrosphingosine through the action
of serine palmitoyltransferase (SPT) [15–17]. This is then
reduced to produce dihydrosphingosine (sphinganine),
which is then acylated by dihydroceramide synthases (also
known CerS) (Fig. 1) [15, 17, 18].
Bioactive sphingolipids including ceramide, ceramide-
1-phosphate (C1P), dihydroceramide (dhCer), sphingosine,
and sphingosine-1-phosphate (S1P) play important roles in
malignant growth [6, 19]. Ceramide is the central molecule
in sphingolipid and glycosphingolipid biosynthesis, and
there are three metabolic pathways leading to ceramide: the
sphingomyelinase pathway, the de novo pathway, and the
exogenous ceramide-recycling pathway [11, 18]. These
metabolic pathways occur in different cellular compart-
ments [3].
Ceramide is an intracellular lipid that has been shown to
regulate the activity of various biochemical and molecular
targets involved in anti-proliferative responses and in
cellular responses including oxidative stress and apoptosis
[20, 21]. The biological effects of ceramide depend on
many parameters, such as cell type, nature of cell receptors,
and their concentration [22].
Ceramide consists of a long-chain amino alcohol
(sphingoid base) carboamidically linked to a fatty acid,
most commonly with a long chain. The primary alcoholic
group of ceramide serves as the attachment site for different
moieties such as phosphate, phosphocholine, and saccha-
rides, producing ceramide-1-phosphate, sphingomyelin and
glycosphingolipids, respectively [4]. Glycosphingolipids
(GSL) are membrane components composed of a group of
membrane lipids in which the lipid portion is embedded in
the outer leaflet of the plasma membrane with the sugar
chain extending to the extracellular space [23–25]. GSLs
are involved in many fundamental cellular processes,
including growth, differentiation, morphogenesis, sensitiv-
ity, and response to exogenous compounds [26]. These
molecules may also modulate cell signaling by controlling
the assembly and specific activities of the plasma membrane
Fig. 1 Pathways of sphingolipid metabolisms
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proteins [27]. GSLs are composed of a sphingoid base and a
long, mostly saturated amide-linked acyl chain. The struc-
ture of the polar head group may vary significantly, ranging
from one neutral monosaccharide residue to big assemblies
of carbohydrates and sialic acid [28, 29].
Glucosylceramide (GlcCer) is an important glyco-
sphingolipid metabolic intermediate [6, 30, 31] which
serves as the starting point in the biosynthesis of a wide
variety of GSLs [32]. The synthesis and organization of
lipids take place at the endoplasmic reticulum (ER) and the
Golgi complex and are precisely regulated. Ceramide is
synthesized at the ER and transported to other locations. It
either undergoes vesicular trafficking to the cis-Golgi,
where it is converted to GlcCer, or gets transported to the
trans-Golgi for conversion to sphingomyelin (SM) [33].
GlcCer is the product of the transfer of glucose by gluco-
sylceramide synthase (GCS) from UDP-glucose to cera-
mide [6, 34]. Studies have shown that GluCer has
proliferative functions on various cells. Therefore, it is
important in the chemotherapeutic drug resistance [6].
This review will focus on the structure and functions of
glucosylceramide synthase and glucosylceramide, and the
roles of glucosylceramide synthase in treatment and drug
resistance of cancer. It will also discuss targeting the glu-
cosylceramide synthase/glucosylceramide pathway for the
treatment of cancer.
Structure and functions of glucosylceramide synthase
and glucosylceramide
Glucosylceramides are present in almost all eukaryotic
organisms and in a few bacteria, and they play a key role in
the synthesis of hundreds of different GSLs [29, 35, 36].
GSLs are characteristic constituents of plasma membranes
of mammalian cells. They may modulate cell proliferation,
differentiation, and cell–cell interaction [37] and play an
important role in the metastatic spread of tumor cells since
GSLs on the cell membrane have been implicated as
functionally important molecules in tumor cell attachment
[38]. They are glycolipids that contain a hydrophilic head
group sugar, D-glucose, and a hydrophobic lipid moiety
[26]. The structures of the sugar head groups and the cer-
amide backbones of many GlcCer from animals, plants,
fungi, and bacteria have demonstrated variety [35]. The
biosynthesis of GlcCer results of biochemical events
leading to complex structures. The above structures are
embedded at the surface of cells by non-covalent interac-
tions between phospholipids and the ceramide part of the
glycolipids. The carbohydrate is endowed of recognition
properties, modulated by the nature of the lipid moiety
responsible for the self-assembling properties of the
whole [39]. GlcCers have been degraded both by a
glucocerebrosidase in lysosomes and by a non-lysosomal
glucocerebrosidase in the cytosol [29].
GlcCers have been found to be involved in many cel-
lular processes such as cell proliferation, oncogenic trans-
formation, differentiation, and tumor metastasis, and more
recently, they have been implicated in venous thrombosis
and in the anticoagulant activity of protein C [26]. GlcCer
functions have been listed as (1) contributing to the phys-
ical properties and physiological functions of membranes,
(2) serving as the basic precursor for over 300 species of
glycosphingolipids found in different mammalian cell
types, and (3) GlcCer synthesis and degradation are
believed to contribute to the control of the level of cera-
mide [35, 40].
GlcCers are formed from ceramide and UDP-glucose by
the microsomal enzyme, UDP-glucose: ceramide d-gluco-
syltransferase also known as GCS (EC 2.4.1.80), that is, a
transmembrane protein localized in the cis/medial Golgi,
with an N-terminal signal-anchor sequence and a C-ter-
minal catalytic domain located in the cytoplasm [14, 23,
41–43]. The rate of reaction under physiological conditions
may depend on the tissue level of UDP-glc, which in turn
depends on the level of glucose in a particular tissue [44].
This enzyme does not possess similarity to other known
glycosyltransferases. The structure of the enzyme is quite
unique since all other glycosyltransferases involved in GSL
synthesis are localized to the lumenal side of the Golgi
apparatus or ER [45]. It catalyzes the transfer of a glucose
moiety from UDP-glucose to the primary hydroxyl group
of ceramide to yield GlcCer with inversion of the anomeric
configuration for synthesis of glucosylceramide [46–48].
The catalytic activity of GSC interferes with the func-
tion of both GlcCer and higher GSLs. These functions
include two phenomena of medical importance. First,
turnover of higher GSLs requires their continuous but
matching degradation. Inhibition of GlcCer biosynthesis by
drugs can reduce the accumulation of higher sphingolipid.
Second, the development of cancer cells toward apoptosis
or proliferation and their level of multidrug resistance
depend on the ratio of ceramide to glycosphingolipids
[42, 43]. The activity of GCS was first determined in 1968
and since then different enzymatic assays have been
developed [49]. This enzyme is located on the cytosolic
membrane leaflet of the Golgi apparatus. From here,
GlcCer can reach the plasma membrane by direct transport,
or it can be modified by further glycosylation in the Golgi
apparatus [37, 50, 51]. Glucose is first glycosylated with
the C1 hydroxyl group of ceramide, and then, the GlcCer
unit serves as a common coupling partner for the oligo-
saccharide donors [52]. This enzyme is also available in the
ER and microsome [53].
It has been shown that human GCS is a glycopro-
tein containing 394 amino acids encoded from 1182
Cancer Chemother Pharmacol (2013) 71:13–20 15
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nucleotides, including a G1C rich, 59 untranslated regions
of 290 nucleotides [34]. GCS is composed of 38-kDa
monomers organized as heterodimers or heterooligomers
with both C and N termini present in the final enzyme form.
The active site of the enzyme is present on the cytosolic face
of the Golgi membrane with some epitopes shielded by
proximity to other parts of the enzyme or Golgi membrane.
In addition, there is an associated protein of 15 kDa found
in conjunction with the enzyme normally found in Golgi
membranes whose specific structure is currently unknown
[38]. Enzyme protein is both tightly membrane bound and is
a minor component of the Golgi membrane. Therefore,
purification of GCS is very difficult [45].
GCS activity is stimulated by a number of means that
increase ceramide concentrations, such as the addition of a
short-chain ceramide and treatment with bacterial sphin-
gomyelinase, endoglycoceramidase, or inhibitors of GCS
synthase [7].
Glucosylceramide synthase in drug resistance
Despite of the presence of many therapeutic approaches
developed continuously for cancer therapy, in clinic,
resistance cases against these approaches are arising at the
same time. For this reason, resistance development is one
of the major obstacles in the struggle between the cancer
cells and the therapeutics.
As well as the known mechanisms for many years,
abnormal sphingolipid metabolism has also been seen as an
effective drug resistance mechanism, recently [27, 54].
Conversion of ceramide into glucosylceramide by the
activity of GCS and therefore intracellular aggregation of
glucosylceramide is generally hold responsible for this type
of mechanism in drug resistance [1, 27, 55]. In 1996,
adriamycin resistance has been reported to be associated
with increased glucosylceramide levels in MCF-7 breast
cancer cells for the first time. This effect of glucosylcera-
mide on drug resistance has been then confirmed in many
other types of cancer cells such as melanoma, leukemia,
and neuroblastoma [27, 47, 55, 56]. However, downregu-
lation or inhibition of GCS results in increased levels of
intracellular ceramide and decreased drug resistance, that
is, reversion of drug resistance [57].
The mechanism underlying the drug resistance that gets
developed with increased glucosylceramide expression is
associated with P-glycoprotein (P-gp) overexpression of
cancer cells [58, 59]. In leukemia, melanoma, colon, and
breast cancer cells, overexpression of GCS causes an
increment in the expression levels of P-gp that results in
drug resistance [60]. P-gp has been also reported to prevent
human AML cells from C8:ceramide-mediated apoptosis,
and inhibition of P-gp resulted in the sensitization of the
cells to apoptosis via C8:ceramide [54]. P-gp expression has
been reported to be responsible for the development of
resistance against the apoptotic effects of C6:ceramide on
HeLa cells [52].
Interestingly, in addition to increased levels of gluco-
sylceramide, increased levels of ceramide also results in
the overexpression of P-gp in breast cancer cells. In 2007,
it has been reported that long-term treatment of MDA-
MB-231 cells with C8:ceramide induces P-gp overexpres-
sion [61]. Moreover, under the stress conditions generated
by the doxorubicin treatment, ceramide has been observed
to trigger the overexpression of GCS and cause the arise of
doxorubicin resistance [62].
High levels of GCS also cause the overexpression of
Bcl-2 gene, an apoptosis suppressor. In adriamycin-resis-
tant K562/AO2 cells, increased levels of Bcl-2 have been
reported rather than that in sensitive K562 cells. Following
the inhibition of GCS by PPMP or downregulation by
siRNA transfection, decreased Bcl-2 gene expression lev-
els have been reported [63]. Likewise, b-catenin- and cSrc
signaling are responsible for the development of drug
resistance due to increased levels of GCS in colon, cervi-
cal, breast, and ovary cancer cells that resist doxorubicin.
In OVCAR-8 human ovarian cancer cells, GCS upregula-
tion has been reported to result in a significant increase in
the levels of cSrc- and b-catenin signaling and also in a
significant decrease in intracellular paclitaxel levels,
showing increased activity of P-gp. In contrast, downreg-
ulation of GCS causes suppression of these signaling
molecules and also of P-gp [64].
The resistance generated as a result of the overexpression
of GCS can be reversed by the inhibition of GCS, P-gp, or any
other responsible genes through the particular inhibitors, by
siRNA transfection, or via using nanoparticles [65]. Siddigui
et al. [66] reported that using oligonucleotide nanoparticles
that have been loaded with antisense GCS reversed resistance
against adriamycin in NCI/ADR-RES cells. The use of these
mixed-backbone oligonucleotides suppressing selectively
GCS overexpression have been also reported to significantly
enhance the sensitivity of human NCI/ADR-RES cells and
also of EMT6/AR1 murine breast cancer cells against doxo-
rubicin. Furthermore, these oligonucleotides decrease the size
of the tumors by increasing the levels of C18:ceramide and
apoptosis mediated by caspases [67]. In breast cancer, in vivo
and in vitro suppression of GCS by GCS siRNA also
decreases P-gp expression and the tumor size; therefore, it
reverses multidrug resistance [68]. Transfection of adriamy-
cin-resistant MCF-7/ADM human breast cancer cells with
both GCS and MDR1 siRNAs results in significant, and more
importantly, efficient reversal of multidrug resistance [69].
Our group recently showed that there were significant
increases in expression levels of imatinib resistant K562 cells
as compared to parental sensitive cells [70].
16 Cancer Chemother Pharmacol (2013) 71:13–20
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Considering all these data, GCS is mainly responsible
for MDR in almost all types of cancer, and targeting and
inhibiting glucosylceramide synthase lead to the reversal of
this MDR, and thus sensitization, and even totally removal
of cancerous cells.
Glucosylceramide synthase in cancer therapy
GCS regulates the balance between ceramide and GlcCer,
meaning that GCS regulates drug sensitivity or resistance
to anticancer drugs [46]. Intracellular accumulation of
ceramide or exogenous ceramides cause anti-proliferative
responses, since ceramide is a strong apoptotic molecule
[51]. There is evidence that ceramide mediates cell death
by apoptotic and non-apoptotic mechanisms in several
systems [27]. Ceramide mediates cell death, while its
detoxification by conversion to glucosylceramide can
inhibit this process [51]. Because GSLs on the cell mem-
brane have been implicated as functionally important
molecules in tumor cell attachment, GluCers play an
important role in the metastatic spread of tumor cells [38].
Because of the propagator effects of GCS in cancer
cells, many researchers have studied targeting GCS in
cancer therapy in order to trigger apoptosis and render
MDR [69]. Previously, Radin has reported that the inhi-
bition of GCS with PDMP, a glucosylceramide analog,
results in an increase in the levels of ceramide and sphin-
gosine and also a decrease in protein kinase C levels in
mouse Ehrlich ascites carcinoma cells and in rat glioma
cells, that is, GCS inhibition enhances the anti-proliferative
effects of chemotherapeutics on cancer cells [71, 72].
Maurer et al. [73] have also reported that GCS inhibition
increases the intracellular ceramide levels and enhances the
cytotoxic effects of 4-HPR and safingol in tumor cells. Not
only in vitro but also in vivo studies have shown that
progression of melanoma cells decreases in response to
GCS suppression, and thus P-gp inhibition [74, 75]. In
neuroepithelioma cells, it has been reported that antisense-
and PDMP-mediated inhibition of GCS decreases the p53-
independent apoptotic effects of the antineoplastic reagent,
retinoid [76]. Furthermore, Gouaze´ et al. [77] have reported
that GCS inhibition leads to increased sensitivity and thus
enhanced effects of paclitaxel, doxorubicin, and vinblastine
via increasing intracellular ceramide levels in MCF-
7-AdrR cells. In 2006, PDMP, the GCS inhibitor, has been
reported to render neuroblastoma cells sensitive against
paclitaxel. This sensitization results in abnormal progres-
sion of cell cycle rather than the induction of apoptosis
[78]. In addition, apoptotic effects of a caspase-dependent
apoptosis inducer peptide molecule, lactoferricin, have
been reported to increase in response to the treatment of
CCRF-CEM and Jurkat T cell leukemia cells with PPMP, a
GCS inhibitor. It has also been shown that the combined
use of lactoferricin and tamoxifen, due to its known
inhibitory effect on GCS function, enhances the apoptotic
effects of lactoferricin, and thus, it leads to increased levels
of apoptosis in Jurkat T cell leukemia cells [79]. The imino
sugar OGT2378 that is also an inhibitor of GCS reduced
the tumorigenic capability of MEB4 melanoma cells [80].
It has been shown that GCS is overexpressed in many
multidrug-resistant cancer cell lines in leukemia, breast
cancer, and renal cell cancer [64]. Treatment of various
kinds of cancer cells with several GCS inhibitors affects
basic cellular functions such as growth, death, and adhe-
sion. Also, recent studies have demonstrated a direct cor-
relation between the development of multidrug resistance
and increased levels of GC [81]. The effects of GCS on
cancer therapy have also been revealed in follicular thyroid
carcinoma cells. In this type of cancer cells, the inhibition
of GCS enhances the anti-cancer effects of camptothecin
and doxorubicin via increasing the level of ceramide syn-
thesis [82]. Recently, it has been also reported that in tumor
cells bearing p53 mutant alleles, GCS inhibition activates
the phosphorylation of p53 and also activates the genes
related with p53-mediated apoptosis, such as Puma,
p21Waf1/Cip1, and Bax. These p53-mutant cancer cells
have also become more sensitive against doxorubicin in
response to GCS inhibition [83].
Moreover, our group has revealed that the suppression
of GCS by PDMP synergistically increases the anti-
proliferative and apoptotic effects of resveratrol on human
acute and chronic myeloid leukemia cell lines [84, 85]. Our
group has also shown that the inhibition of GCS with
PDMP increased anti-proliferative and apoptotic effects of
imatinib [86], nilotinib [87], and dasatinib [88] on chronic
myeloid leukemia cells synergistically. GCS inhibition
causes enhanced cytotoxic and apoptotic responses in
human prostate cancer cells in response to docetaxel
treatment [89]. It was also demonstrated that inhibition of
GCS reversed resistance to doxorubicin and vincristine in
leukemia [90, 91].
Accumulating literature in this area strengthen the
importance of bioactive sphingolipid metabolism for the
diagnostic and therapeutic applications in various cancers.
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